Loading...
Docoh
Log in Free sign up

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.

Company profile

Ticker
SRPT
Exchange
NASDAQ
Website
www.sareptatherapeutics.com
CEO
Douglas Ingram
Employees
Incorporated
Delaware
Location
Massachusetts
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...
Former names
ANTIVIRALS INC, AVI BIOPHARMA INC
SEC CIK
0000873303
Corporate docs
Subsidiaries
Sarepta Securities Corp. • ST International Holdings • Sarepta Therapeutics Three, LLC ...
IRS number
930797222

SRPT stock data

News

From Benzinga Pro
RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $182
9 Aug 22
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $160 to $182.
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
8 Aug 22
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
8 Aug 22
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and Harvard.
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
3 Aug 22
RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $160
3 Aug 22

Press releases

From Benzinga Pro
Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
8 Aug 22
-Following internal corroboration of published results on the MyoAAV platform, Sarepta secures exclusive license for Duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications -The
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Jul 22
CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 29, 2022 that were previously
Thinking about trading options or stock in Sarepta Therapeutics, Apple, General Electric, Microsoft, or Meta Platforms?
29 Jul 22
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRPT, AAPL, GE, MSFT, and META.
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
29 Jul 22
Sarepta Therapeutics' Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
6 Jul 22

Analyst ratings and price targets

Last 3 months
Current price
Average target
$136.67
Low target
$93.00
High target
$182.00
RBC Capital
Maintains
Outperform
$182.00
9 Aug 22
Morgan Stanley
Maintains
Equal-Weight
$100.00
3 Aug 22
Credit Suisse
Maintains
Neutral
$93.00
3 Aug 22
Needham
Maintains
Buy
$162.00
29 Jul 22
Cantor Fitzgerald
Maintains
Overweight
$128.00
24 Jun 22
Goldman Sachs
Maintains
Buy
$155.00
24 May 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

2 Aug 22
18 Aug 22
31 Dec 22

Financial summary

Financial statements Chart SRPT financial data
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 887.06M 887.06M 887.06M 887.06M 887.06M 887.06M
Cash burn (monthly) 118.82M 68.27M 76.03M 41.84M 22.27M 26.8M
Cash used (since last report) 195.67M 112.43M 125.21M 68.89M 36.68M 44.14M
Cash remaining 691.39M 774.63M 761.86M 818.17M 850.39M 842.92M
Runway (months of cash) 5.8 11.3 10.0 19.6 38.2 31.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

SRPT insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Jun 22 Michael Andrew Chambers Common Stock Grant Acquire A No No 0 4,908 0 4,908
2 Jun 22 Michael Andrew Chambers Stock Option Common Stock Grant Acquire A No No 72.58 8,329 604.52K 8,329
2 Jun 22 Kathryn Jean Boor Common Stock Grant Acquire A No No 0 4,908 0 4,908
2 Jun 22 Kathryn Jean Boor Stock Option Common Stock Grant Acquire A No No 72.58 8,329 604.52K 8,329
1 Jun 22 Ryan Edward Brown Common Stock Payment of exercise Dispose F No No 72.67 54 3.92K 25,841
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q2 2022

SRPT institutional ownership history Ownership history
86.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 319 325 -1.8%
Opened positions 39 52 -25.0%
Closed positions 45 69 -34.8%
Increased positions 92 92 –
Reduced positions 129 119 +8.4%
13F shares Current Prev Q Change
Total value 5.66B 5.89B -3.9%
Total shares 76.07M 76.01M +0.1%
Total puts 961.4K 883.1K +8.9%
Total calls 1.18M 1.05M +12.4%
Total put/call ratio 0.8 0.8 -3.2%
Largest owners Shares Value Change
Vanguard 8.42M $631.17M +1.3%
JHG Janus Henderson 7.23M $542.17M -3.0%
BLK Blackrock 5.61M $420.35M +1.1%
Sands Capital Management 3.71M $278.18M -22.4%
Capital Ventures International 3.58M $194.09M 0.0%
Avoro Capital Advisors 3.39M $254.11M +8.1%
EcoR1 Capital 2.87M $215M +38.6%
Wellington Management 2.77M $207.55M +3.3%
STT State Street 2.32M $173.64M +12.6%
BK Bank Of New York Mellon 1.99M $149.24M +0.8%
Largest transactions Shares Bought/sold Change
Sands Capital Management 3.71M -1.07M -22.4%
Point72 Asset Management 425.51K -1.02M -70.6%
EcoR1 Capital 2.87M +798.51K +38.6%
GS Goldman Sachs 1.41M +486.87K +52.7%
Camber Capital Management 1.85M +475K +34.5%
Logos Global Management 400K +400K NEW
BMO Bank of Montreal 107.6K -373.77K -77.6%
American Century Companies 1.18M +365.38K +44.6%
PRU Prudential Financial 81.97K -314.1K -79.3%
Varenne Capital Partners 0 -295.73K EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • PTC • Biogen • Vertex Pharmaceuticals • Arrowhead Pharmaceuticals • Alexion Pharmaceuticals • Roche • FibroGen • Shire • PTC Therapeutics

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: accrual, attrition, Beam, began, built, Carlo, Chief, construction, core, half, Henogen, hypomagnesemia, Italfarmaco, landlord, lattice, letter, Monte, notify, output, pre, reauthorize, reopened, SA, shell, simulation, tenant, Undiscounted, Unvested, withdrew
Removed: announcing, begun, contractually, delivery, Delta, facilitating, MOMENTUM, narrow, referencing, referred, structured, unconsolidated, uninterpretable
From filing 10-Q 2022 Q2
Financial reports
View all
10-Q
2022 Q2
Quarterly report
2 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
3 Nov 21
10-Q
2021 Q2
Quarterly report
4 Aug 21
10-Q
2021 Q1
Quarterly report
5 May 21
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
Current reports
View all
8-K
Departure of Directors or Certain Officers
3 Jun 22
8-K
Departure of Directors or Certain Officers
21 Apr 22
8-K
Departure of Directors or Certain Officers
5 Apr 22
8-K
Results of Operations and Financial Condition
10 Jan 22
8-K
Departure of Directors or Certain Officers
17 Nov 21
8-K
Entry into a Material Definitive Agreement
15 Oct 21
8-K
Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful
27 Sep 21
8-K
Submission of Matters to a Vote of Security Holders
3 Jun 21
8-K
Regulation FD Disclosure
18 May 21
8-K
Results suggest a highly potent next-generation treatment that could offer greater efficacy with less frequent dosing
3 May 21
Registration and prospectus
View all
S-8
Registration of securities for employees
2 Aug 22
S-3ASR
Automatic shelf registration
2 Mar 22
424B5
Prospectus supplement for primary offering
15 Oct 21
424B5
Prospectus supplement for primary offering
12 Oct 21
S-8
Registration of securities for employees
5 Aug 20
D
$400M in equity, sold $400M, 1 investor
28 Feb 20
D
$30.5M in equity, sold $30.5M, 1 investor
25 Nov 19
S-3ASR
Automatic shelf registration
14 Nov 19
S-8
Registration of securities for employees
11 Sep 19
424B5
Prospectus supplement for primary offering
7 Mar 19
Proxies
View all
DEF 14A
Definitive proxy
25 Apr 22
DEFA14A
Additional proxy soliciting materials
20 Apr 21
DEF 14A
Definitive proxy
20 Apr 21
DEFA14A
Additional proxy soliciting materials
21 Apr 20
DEF 14A
Definitive proxy
21 Apr 20
PRE 14A
Preliminary proxy
8 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
DEFA14A
Additional proxy soliciting materials
26 Apr 18
DEF 14A
Definitive proxy
25 Apr 18
Other
View all
UPLOAD
Letter from SEC
15 Apr 20
CORRESP
Correspondence with SEC
14 Apr 20
UPLOAD
Letter from SEC
12 Apr 20
CT ORDER
Confidential treatment order
9 Nov 18
CT ORDER
Confidential treatment order
11 Sep 17
CT ORDER
Confidential treatment order
18 Jan 17
CT ORDER
Confidential treatment order
3 Oct 16
EFFECT
Notice of effectiveness
4 May 15
CORRESP
Correspondence with SEC
3 May 15
UPLOAD
Letter from SEC
28 Apr 15
Ownership
View all
4
Sarepta Therapeutics / Kathryn Jean Boor ownership change
6 Jun 22
4
Sarepta Therapeutics / Michael Andrew Chambers ownership change
6 Jun 22
3
Sarepta Therapeutics / Michael Andrew Chambers ownership change
6 Jun 22
3
Sarepta Therapeutics / Kathryn Jean Boor ownership change
6 Jun 22
4
Sarepta Therapeutics / Ryan Edward Brown ownership change
3 Jun 22
4
Sarepta Therapeutics / Stephen Mayo ownership change
9 Mar 22
4
Sarepta Therapeutics / Claude Nicaise ownership change
8 Mar 22
4
Sarepta Therapeutics / MARY ANN GRAY ownership change
8 Mar 22
4
Sarepta Therapeutics / Hans Lennart Rudolf Wigzell ownership change
8 Mar 22
4
Sarepta Therapeutics / M KATHLEEN BEHRENS ownership change
8 Mar 22

Patents

View all
Utility
Exon Skipping Compositions for Treating Muscular Dystrophy
18 Aug 22
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Utility
Exon Skipping Oligomers for Muscular Dystrophy
11 Aug 22
Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
Utility
Exon skipping oligomer conjugates for muscular dystrophy
26 Jul 22
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
Utility
Exon skipping oligomer conjugates for muscular dystrophy
12 Jul 22
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
Utility
Processes for preparing oligomers
12 Jul 22
Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer).

Transcripts

View all
2022 Q2
Earnings call transcript
2 Aug 22
2022 Q1
Earnings call transcript
5 May 22
2021 Q4
Earnings call transcript
2 Mar 22
2021 Q3
Earnings call transcript
4 Nov 21
2021 Q2
Earnings call transcript
5 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
2 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
6 Aug 20
2020 Q1
Earnings call transcript
6 May 20

Reddit threads

View all